Kansɛri min bɛ muso wolonugu la o de filanan ye kansɛri suguya bɛɛ la cɛw la diɲɛ fan bɛɛ, ni a jateminɛnan ko banabaatɔ miliyɔn 1.276 wɛrɛ yera san 2018 la, min bɛ kɛ 7.1% kansɛri banabaatɔ cɛw la.
Bana minnu bɛ sɔrɔ sumaya fɛ olu ka ca: sumaya min bɛ sɔrɔ cɛya ni musoya fɛ, sumaya min bɛ sɔrɔ musoya fɛ, ani sumaya min bɛ sɔrɔ cɛya ni musoya ka baaraɲɔgɔnya fɛ.
Nka, saya hakɛ bɛ yɛlɛma kosɛbɛ marabolo dɔ la, ni Afiriki Tilebinyanfan bɛ dananfɛn kulu duurunan na diɲɛ kɔnɔ min ka jugu kansɛri bana ma, ani Nizeriya min jama ni sɔrɔ ka ca o mara kɔnɔ.
Nigéria jamana na, kansɛri min bɛ muso wolonugu kan, o de ka teli ka cɛw faga, a bɛ mɔgɔ 32.8 bɔ wa a bɛ mɔgɔ 16.3 faga mɔgɔ 100,000 o mɔgɔ 100,000.
O ka ca ni farafina tilebiyanfan ka saya hakɛ ye siɲɛ fila.
Bana in sɔrɔli ka mɛɛn, fɛɛrɛw dɛsɛlen sɛgɛsɛgɛli ni a sɔrɔli kama, ani a sɛbɛnni n'a jirali dɔgɔya, o de ye a sababu ye ka mɔgɔ caman faga Nijeria.
Ameriki jamana na, biɲɛdimi ye a sababu filanan ye ka mɔgɔ caman faga kansɛri bana fɛ cɛw la, a bɛ cɛ 400000 ɲɔgɔn faga san o san.
Bana minnu bɛ sɔrɔ musoyalabana fɛ olu hakɛ bɛ ka dɔgɔya dɔɔni dɔɔni kabini san 1990 daminɛni, nka a bele ye kɛnɛya ko gɛlɛya dɔ ye.
A ka ca a la, sumayabana ye bana juguba ye, kɛrɛn kɛrɛnnenya la, yɔrɔ minnu na dɔgɔtɔrɔw ka dɔgɔ ani yɔrɔ minnu la, sumayabana sɛgɛsɛgɛli kɛli ka gɛlɛn.
Nka, a daminɛni joona ni a furakɛli bɛ se ka bana kuntaala fisaya kosɛbɛ ani ka saya hakɛ dɔgɔya.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Kunnafoni nafama: kɛnɛya']
['Nin gafe in labɛnna kalan ni kunnafoni dɔrɔn de kama, a tɛ sɔrɔ dɔgɔtɔrɔ ka ladili wala kɛnɛyabaarakɛla ka baara kɛcogo la.']
["Kunnafoni minnu dira aw ma, aw man kan ka olu kɛ ka banaw furakɛ. Mɔgɔ minnu b'u yɛrɛ furakɛ, olu ka kan ka dɔgɔtɔrɔ dɔ ka dɛmɛ ɲini."]
["Aw ye aw janto nin na: ɛntɛrinɛti min bɛ jabi di ɲininkaliw jaabiliw kan, o dabali ka jugu kɛrɛnkɛrɛnnenya la n'a bɛ tali kɛ jatidenw de kan. Misali la, mɔgɔ hakɛ min ka bana kofɔra."]
['Aw bɛ ladilikan ɲini tuma bɛɛ aw ka dɔgɔtɔrɔ fɛ walima kɛnɛya baarakɛla dɔ wɛrɛ min bɛ se ka aw dɛmɛ ka aw ka bana furakɛ. Aw kana dɔgɔtɔrɔ ka ladilikan bila ka suma walima ka mɛn a ɲini na sabu aw ye fɛn dɔ kalan nin siti kan. Ni aw hakili la ko aw ka bana bɛ se ka juguya joona, aw ye 911 wele walima aw ka taa aw ka dɔgɔtɔrɔso la joona joona. Nin siti tɛ dɔkɔtɔrɔ ni banabagatɔ ka jɛɲɔgɔnya jira. BioMedLib ni a ka baaradenw, walima nin siti dɛmɛbaga si tɛ kuma si jira walima ka jira, nin kunnafoniw wala u labaarali kama.']
['Kunnafoni min lakodɔnna:']
["Digital Millennium Copyright Act san 1998, 17 U.S.C. § 512 (a DMCA) bɛ sariya sigi ka ɲɛsin mɔgɔ ma min b'a miiri ko fɛn min bɛ sɔrɔ intɛrinɛti kan, o bɛ tɔɲɔ a ka sariyaw la Ameriki jamana ka sariya kɔnɔ. "]
['Ni i dara a la kô i ka site web ni a baara tchogow bè i ka lakananifènw la, i (walima i ka lasigiden) bè se ka i yèrè ka lakananifènw bila ka o site web ni a baara tchogow bila kènèkan.']
['Waajibi don kunnafoniw ci kɛtɔ ka kɛ sɛbɛn ye e-mail fɛ (e-mail de kan ka lajɛ sɛbɛn ɲɛ Kunnafoniw lajɛ yɔrɔ la).']
["DMCA bɛ a ɲini i ka kunnafoni sɛbɛn bɔlɔlɔw kan kojugukɛ sɛbɛn bɛ sɛbɛn min kɔnɔ, o ka kan ka nin kunnafoniw fara a kan: (1) sɛbɛnni kɛtɔ ka sɛbɛnni kɛ min bɛ sɛbɛnni kɛ ni a ma kɛ kojugukɛ sɛbɛn ye; (2) sɛbɛnni kɛtɔ ka fɛn kofɔlen in kofɔ ani kunnafoni minnu bɛ a to an bɛ se ka fɛn kofɔlen in sɔrɔ; (3) i ka ladɛrɛsi, i ka ladɛrɛsi, telefɔni nimɔrɔ ani i ka ladɛrɛsi; (4) i ka kumaɲɔgɔnya sɛbɛn ko i dalen b'a la ko i bɛ a dɔn ko i bɛ ka fɛn kofɔlen in kɛ ni sariya min ye, o ma di sɛbɛnnikɛbaga ma, a ka ladɛrɛsi tigi, walima sariya wɛrɛ; "]
['(5) a ka seereyasɛbɛ sɛbɛntiya, ko seereyasɛbɛ minɛnen bɛ kojugubakɛlaw kama, ko kunnafoni min bɛ o sɛbɛntiya kɔnɔ, ko tiɲɛ don ani ko i yamaruyalen don ka yamaruya di ka kɛwalew kɛ minnu bɛ tiɲɛni kɛ; ']
['ani (6) sɛbɛn dɔ ka boloci walima ɛkitɔrɔniki sɛbɛn sɛbɛn tigi fɛ walima mɔgɔ min yamaruyara ka baara kɛ sɛbɛn tigi tɔgɔla. ']
['Ni kunnafoni fɔlen ninnu bɛɛ ma fara ɲɔgɔn kan, o bɛ se ka kɛ sababu ye ka mɛn baara kɛli la i ka sɛbɛn kɔnɔ.']
['Ɲɔgɔnkunbɛn']
['Sɛbɛn ɲɛ Ɲiningaliw / ladiliw']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɲɔgɔn fɛ']
['BioMedLib bɛ baara kɛ ni ɔridinatɛri ye (mansin ka kalan aligoritimiw) walasa ka ɲininkaliw ni jaabiw di ɲɔgɔn ma.']
['An bɛ a daminɛ ni gafew miliyɔn 35 ye ka bɔ PubMed/Medline. Ani fana, ɛntɛrinɛti sitiw ka bɔ RefinedWeb.']
